Abacavir, Lamivudine, and Zidovudine

Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Inhibits
  • Induces
  • Drug Interactions
  • Dosage

Brand Names


Austria: Trizivir; Belgium: Trizivir; Bulgaria: Trizivir; Cyprus: Trizivir; Czech Republic: Trizivir; Denmark: Trizivir; Estonia: Trizivir; Finland: Trizivir; France: Trizivir; Germany: Trizivir; Greece: Trizivir; Hungary: Trizivir; Ireland: Trizivir; Italy: Trizivir; Latvia: Trizivir; Lithuania: Trizivir; Luxembourg: Trizivir; Malta: Trizivir; Netherlands: Trizivir; Poland: Trizivir; Portugal: Trizivir; Romania: Trizivir; Slovakia: Trizivir; Slovenia: Trizivir; Spain: Trizivir; Sweden: Trizivir; UK: Trizivir.

North America

Canada: Trizivir; USA: Trizivir.

Latin America

Argentina: Tricivir, Trivudin, Zidomuv; Mexico: Trizivir.

Drug combinations


Abacavir Sulfate: (C~14~H~18~N~6~O)~2~ H~2~SO~4~. Mw: 670.74. (1S,4R)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol sulfate (2:1). CAS-188062-50-2 (1997).

Lamivudine: C~8~H~11~N~3~O~3~S. Mw: 229.26. (1) 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-,(2R-cis)-; (2)(-)-1-[(2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. CAS-134678-17-4 (1992).

Zidovudine: C~10~H~13~N~5~O~4~. Mw: 267.24. (1) Thymidine, 3′-azido-3′-deoxy-; (2) 3′-Azido-3′-deoxythymidine. CAS-30516-87-1 (1987).

Pharmacologic Category

Anti-infective Agents, Antiretrovirals, Nucleoside and Nucleotide Reverse Transcriptase Inhibitors. (ATC-Code: J05AR04).

Mechanism of action

Inhibition of reverse transcriptase via DNA chain termination after incorporation of the nucleoside analog as well as delay of emerging mutations conferring resistance.

Therapeutic use

Treatment of HIV infections in combination with other antiretroviral agents.

Pregnancy and lactiation implications

Unlabeled use


Hypersensitivity to abacavir, lamivudine, zidovudine, or any component of the formulation. Renal (CrCl ≤50 mL/minute) or hepatic impairment.

Warnings and precautions

May cause redistribution of fat. Hematologic toxicity may occur (neutropenia, anemia; use with caution in bone marrow compromise). Hypersensitivity reactions have occurred (increased risk in patients with HLA-B*5701 allele). Immune reconstitution syndrome may develop. Lactic acidosis and severe hepatomegaly with steatosis have been reported (caution in risk factors for liver disease). Clinical exacerbations after discontinuing therapy for chronic hepatitis B in HIV patients have occurred. Caution in risk factors for coronary heart disease. Risk of myopathy and myositis (with prolonged use). Should always be used as part of a multidrug regimen. Should not be used in CrCl ≤50 mL/minute. Caution in combination with interferon alfa with or without ribavirin in HIV/HBV coinfected patients. Avoid use in children.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart